在老年患者的侵入性阿斯伯吉洛症治疗当前的挑战
Sara Fueyo Álvarez1,2, Elena Valle Calonge1,2,3, Julieth Andrea Caballero Velasquez1,2
1Hospital Monte Naranco, 33012 Oviedo, Spain.
Journal of fungi (Basel, Switzerland)
|September 23, 2025
概括
在80岁以上的老年患者中,侵入性阿斯伯吉洛症 (IA) 显示出高死亡率. 伊萨夫可纳比伏利可纳更安全,更有效,突出了个性化IA治疗策略的必要性.
科学领域:
- 老年医学 老年医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 侵入性阿斯伯吉洛症 (IA) 对老年人构成重大威胁,特别是那些患有慢性呼吸道疾病和长期使用皮质类固醇的人.
- 人口老龄化在管理像IA这样的严重真菌感染方面提出了独特的挑战.
研究的目的:
- 评估voriconazole与isavuconazole在治疗80岁以上患者IA中的临床结果,安全性和疗效.
- 确定与老年IA患者死亡率相关的风险因素.
主要方法:
- 一项涉及45名80岁以上IA诊断的患者的研究.
- 临床,生化和真菌生物标志物的评估.
- 沃里康纳和伊萨夫康纳治疗的比较,分析死亡率和不良事件.
主要成果:
- 总体死亡率为35.61%,白细胞瘤,中性恋和淋巴缺血被确定为显著的危险因素.
- 与沃里科纳相比 (61.5%的死亡率,60%的不良反应),伊萨武科纳显示30天死亡率显著降低 (19.2%) 和不良反应较少 (5%).
- 沃里康纳显示出更大的药理动力学变异性,其中76.9%的病例超出治疗范围.
结论:
- 沃里康纳可能不是治疗老年人群 (80岁以上) 的IA的最佳选择.
- 伊萨夫可纳在这个人群中提供了更有利的安全性和有效性概况.
- 个性化治疗策略和多学科方法对于改善老年IA患者的治疗结果至关重要.
相关概念视频
01:15Drug Dosing: Geriatric Patients
228
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
228
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
238
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
238
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
229
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
229
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188